Clinical Trials Browser

PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy

NCT05551117 2026-02-09

Tamarack

Phase 2 Terminated

192 enrolled 20 charts

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Carcinoma, Small Cell, Small Cell Lung Carcinoma, Prostatic Neoplasms, Castration-Resistant

NCT05701007 2026-01-29

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

Completed

1,083 enrolled 29 charts

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT06764485 2026-01-28

rechARge

Phase 3 Recruiting

960 enrolled

Genitourinary

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT04647526 2026-01-13

SPLASH

Phase 3 Active not recruiting

455 enrolled 18 charts

Genitourinary

Prostatic Neoplasms

NCT01995058 2026-01-08

Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC

Phase 2 Terminated

54 enrolled 11 charts

Genitourinary

Prostatic Neoplasms

NCT06072196 2025-12-31

A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Completed

3,017 enrolled 5 charts

Genitourinary

Prostatic Neoplasms

NCT06421935 2025-12-19

M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)

Phase 1 Active not recruiting

141 enrolled

Gynecologic

Ovarian Neoplasms

NCT04446117 2025-12-18

CONTACT-02

Phase 3 Active not recruiting

575 enrolled 13 charts

Genitourinary

Prostatic Neoplasms

NCT04034095 2025-12-15

A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan

Completed

979 enrolled

Genitourinary

Prostatic Neoplasms

NCT05914116 2025-11-21

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

Phase 1/2 Recruiting

862 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT03480646 2025-10-29

ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer

Phase 1/2 Completed

175 enrolled 23 charts

Tumor-Agnostic

Neoplasms

NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Phase 1/2 Terminated

137 enrolled 31 charts

BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT04631601 2025-10-07

Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)

Phase 1/2 Terminated

65 enrolled

Bites and Stings

NCT04666129 2025-08-17

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

Phase 1 Completed

48 enrolled

Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT05204927 2025-07-31

177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

Phase 3 Active not recruiting

439 enrolled

Genitourinary

Prostatic Neoplasms

NCT05177042 2025-07-25

Trial of ARV-110 and Abiraterone in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Phase 1 Completed

45 enrolled

Genitourinary

Prostatic Neoplasms

NCT05288166 2025-06-27

CYCLONE 3

Phase 3 Active not recruiting

925 enrolled 12 charts

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms, Urogenital Neoplasms

NCT03072238 2025-06-06

IPATential150

Phase 3 Completed

1,101 enrolled 35 charts

Genitourinary

Prostatic Neoplasms

Clinical Trials

IDeate-Prostate02

CELLO-1

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

InavoPC

A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer

TulmiSTAR-02

AcTFirst

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

Tamarack

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

rechARge

SPLASH

Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC

A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)

CONTACT-02

A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

Trial of ARV-110 and Abiraterone in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

CYCLONE 3

IPATential150